• About us
  • Team
  • Privacy Policy
  • Contact
Wednesday, November 18, 2026
  • Login
No Result
View All Result
World's first weekly chronicle of development news
  • Blitz Highlights
    • Special
    • Spotlight
    • Insight
    • Entertainment
    • Sports
  • Opinion
  • Legal
  • Perspective
  • Nation
    • East
    • West
    • North
    • South
  • Business & Economy
  • World
  • Hindi Edition
  • International Editions
    • Dubai
    • Tanzania
    • United Kingdom
    • USA
  • Blitz India Business
  • Blitz Highlights
    • Special
    • Spotlight
    • Insight
    • Entertainment
    • Sports
  • Opinion
  • Legal
  • Perspective
  • Nation
    • East
    • West
    • North
    • South
  • Business & Economy
  • World
  • Hindi Edition
  • International Editions
    • Dubai
    • Tanzania
    • United Kingdom
    • USA
  • Blitz India Business
No Result
View All Result
World's first weekly chronicle of development news
No Result
View All Result

CDSCO approves Cipla to distribute, market inhaled insulin in India

by Blitz India Media
December 11, 2024
in News
0
Cipla
Blitz Bureau

NEW DELHI: Indian regulator Central Drugs Standard Control Organisation (CDSCO) has approved Cipla to exclusively distribute and market inhaled insulin in the country, the drugmaker said on December 10. The insulin called Afrezza is created and manufactured by MannKind Corporation, and is used to improve glycemic control in adults with diabetes mellitus.

“Afrezza is a rapid-acting insulin delivered through an inhaler as compared to current insulins which are given as injections. Taken at the beginning of a meal, Afrezza dissolves rapidly upon oral inhalation into the lungs and delivers insulin quickly to the bloodstream,” the company said.

Cipla aims to make the drug accessible to all and empower millions to take control of their health with greater ease. The company noted that Afrezza will start working in as early as 12 minutes and help in reducing the rapid increase seen in sugar levels with meals.

The effect of Afrezza lasts for about 2-3 hours and it closely resembles the body’s own response to insulin. This is the first and only non-injectable insulin to be developed for patients of both type 1 and type 2 diabetes mellitus, the company said.

“By reducing the need for multiple daily insulin injections, we are offering a convenient solution for people living with diabetes mellitus, particularly those who are uncomfortable with needles, helping them manage their condition more effectively,” said Umang Vohra, Managing Director and Global CEO, Cipla.

Afrezza has been evaluated in over 70 clinical studies involving more than 3,000 patients overall. A phase 3 clinical trial conducted on 216 patients in India showed a significant reduction in HbA1c levels when patients added Afrezza to oral anti-diabetes medications.

The availability of insulin to be inhaled through the lungs will provide a new and innovative option for patients with diabetes mellitus, the company said.

Afrezza has been approved in the US for more than 10 years and has been prescribed for tens of thousands of patients. MannKind will supply Afrezza to Cipla, who will be then responsible for sales and marketing activities in India.

Related Posts

blitzindia-daily-news
News

Earshot honour puts Mahindra’s EV model on global stage

November 18, 2026
Gurnoor Brar
News

Gurnoor Brar reprimanded for Code of Conduct breach

November 17, 2026
India Pushes Electronics Manufacturing Beyond Assembly
News

India’s electronics exports surge 44 pc to $31.97 billion in Apr-Sep

November 17, 2026
Solar panels supplying power in Africa
News

Amazon to invest $7 billion in India renewable energy by 2030

November 17, 2026
India Growth
News

PM Modi takes India’s Indo-Pacific agenda to Manila

November 17, 2026
petrol diesel price
News

Fuel price spike pushes wholesale inflation to 12.29pc

November 16, 2026
Load More
Next Post
Rohit

Pujara advises Rohit to score first 20-30 runs steadily

Recent News

blitzindia-daily-news
News

Earshot honour puts Mahindra’s EV model on global stage

by Blitz India Media
November 18, 2026
0

MUMBAI, 18 November Mahindra Last Mile Mobility Limited was named winner of the Earthshot Prize 2026 in the Clean Our...

Read moreDetails
Gurnoor Brar

Gurnoor Brar reprimanded for Code of Conduct breach

November 17, 2026
India Pushes Electronics Manufacturing Beyond Assembly

India’s electronics exports surge 44 pc to $31.97 billion in Apr-Sep

November 17, 2026
Solar panels supplying power in Africa

Amazon to invest $7 billion in India renewable energy by 2030

November 17, 2026
India Growth

PM Modi takes India’s Indo-Pacific agenda to Manila

November 17, 2026

Blitz Highlights

  • Special
  • Spotlight
  • Insight
  • Entertainment
  • Health

International Editions

  • US (New York)
  • UK (London)
  • Middle East (Dubai)
  • Tanzania (Africa)

Nation

  • East
  • West
  • South
  • North
  • Hindi Edition

E-paper

  • India
  • Hindi E-paper
  • Dubai E-Paper
  • USA E-Paper
  • UK-Epaper
  • Tanzania E-paper

Useful Links

  • About us
  • Team
  • Privacy Policy
  • Contact

©2024 Blitz India Media -Building A New Nation

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

    No Result
    View All Result
    • Blitz Highlights
      • Special
      • Spotlight
      • Insight
      • Entertainment
      • Sports
    • Opinion
    • Legal
    • Perspective
    • Nation
      • East
      • West
      • North
      • South
    • Business & Economy
    • World
    • Hindi Edition
    • International Editions
      • Dubai
      • Tanzania
      • United Kingdom
      • USA
    • Blitz India Business

    ©2024 Blitz India Media -Building A New Nation